MedTrace Logo

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

NCT00003181 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2013-12-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining chemotherapy with interleukin-2 and GM-CSF may be a more effective treatment for kidney cancer.

PURPOSE: Phase II trial to study the effectiveness of low-dose interleukin-2, vinblastine, and GM-CSF in treating patients with metastatic kidney cancer.

Conditions

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

sargramostim

DRUG

vinblastine sulfate

Sponsors & Collaborators

  • Hope Cancer Institute, Inc.

    lead INDUSTRY

Principal Investigators

  • Raj Sadasivan, MD, PhD · Hope Cancer Institute, Inc.

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003181 on ClinicalTrials.gov